Survivin as a Preferential Target for Cancer Therapy
Open Access
- 12 February 2014
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (2), 2494-2516
- https://doi.org/10.3390/ijms15022494
Abstract
Cancer is typically a consequence of imbalance between cell death and proliferation in a way favorable to cell proliferation and survival. Most conventional cancer therapies are based on targeting rapidly growing cancerous cells to block growth or enhance cell death, thereby, restoring the balance between these processes. In many instances, malignancies that develop resistance to current treatment modalities, such as chemotherapy, immunotherapy, and radiotherapy often present the greatest challenge in subsequent management of the patient. Studies have shown that under normal circumstances, cells utilize different death mechanisms, such as apoptosis (programmed cell death), autophagy, mitotic catastrophe, and necrosis to maintain homeostasis and physiological integrity of the organism, but these processes often appear to be altered in cancer. Thus, in recent years developing various strategies for administration of cytotoxic chemotherapeutics in combination with apoptosis-sensitizing reagents is receiving more emphasis. Here, we review the properties of the anti-apoptotic protein, survivin, a member of the inhibitor of apoptosis protein (IAP) family and the clinical feasibility and anti-cancer potential of drugs targeting this protein. We also discuss some key points and concerns that should be taken into consideration while developing drugs that target apoptotic proteins, such as survivin.Keywords
This publication has 143 references indexed in Scilit:
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic ActivityJournal of Biological Chemistry, 2010
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Compartmentalized Phosphorylation of IAP by Protein Kinase A Regulates CytoprotectionMolecular Cell, 2007
- Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the familyEMBO Reports, 2006
- Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell deathOncogene, 2000
- The Hallmarks of CancerCell, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999